Karyopharm Therapeutics Inc Corporate Call Transcript
Good morning. My name is Victor, and I'll be your conference operator for today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics conference call to announce the FDA accelerated approval of XPOVIO. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Mr. Chris Primiano, Karyopharm's Chief Business Officer and General Counsel. You may begin.
Thank you, Victor, and thank you all for joining us on this very exciting occasion to discuss the FDA's accelerated approval of XPOVIO, also known as selinexor, for the treatment of adult patients with highly refractory multiple myeloma. This is Chris Primiano, and I'm joined today by Dr. Sharon Shacham, Founder, President, Chief Scientific Officer and Inventor of XPOVIO; Dr. Michael Kauffman, Chief Executive Officer; Mr. Perry Monaco, Senior Vice President of Sales; and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |